2026-04-14T03:25:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/101832025-10-24T08:57:06Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin Torres-Duran, María Montero Martínez, Carmen Priegue Carrera, Ana Amaro, Rosanel Barrecheguren, Miriam Barrio Guirado, MªAngeles García-Meseguer, Pilar López-Campos Bodineau, José Luis Calle Rubio, Myriam Montoro-Ronsano, J. Bruno Miravitlles, Marc Institut Català de la Salut [Torres-Durán M] Pneumology Department, Hospital Álvaro Cunqueiro, NeumoVigo I+i Research Group, IIS Galicia Sur, Vigo, Spain. [López-Campos JL] Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. Medical and Surgery Unit for Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain. [Calle Rubio M] Pneumology Department, Research Institute of Hospital Clínico San Carlos (IdISSC), Department of Medicine, Faculty of Medicine, University Complutense of Madrid, Madrid, Spain. [Montero-Martínez C] Pneumology Department, Hospital Universitario de A Coruña, A Coruña, Spain. [Priegue Carrera A] Nursing Unit, Hospital Álvaro Cunqueiro, Pontevedra, Spain. [Amaro Rodríguez R] Pneumology Department, Hospital Clínic, Barcelona, Spain. [Barrecheguren M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Barrio Guirado MÁ, García-Meseguer P] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Montoro-Ronsano JB] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Pulmons - Malalties - Tractament Alfa 1-antitripsina - Ús terapèutic Teràpia intravenosa CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Serpins::alpha 1-Antitrypsin Other subheadings::Other subheadings::/therapeutic use ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Intravenous::Infusions, Intravenous DISEASES::Respiratory Tract Diseases::Lung Diseases COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::serpinas::alfa 1-antitripsina Otros calificadores::Otros calificadores::/uso terapéutico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración intravenosa::infusiones intravenosas ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares Alpha-1 antitrypsin deficiency; Sugmentation therapy; Self-administration Deficiència d'alfa-1 antitripsina; Teràpia d'augment; Autoadministració Deficiencia de alfa-1 antitripsina; Terapia de aumento; Autoadministración Purpose: Administration of exogenous alpha-1 antitrypsin (AAT) is the only specific therapy for the management of pulmonary morbidity in patients with AAT deficiency. It requires weekly or biweekly intravenous infusions, which may impact patient independence and quality of life. Self-administration of AAT therapy is an alternative to reduce the burden for patients who require AAT therapy. We presented herein experts’ recommendations for the implementation of a program for the self-administration of AAT. Methods: This project was conducted using a modified nominal group technique and was undertaken in two online meetings involving the participation of 25 experts: specialists in pulmonology (n=17), nurses (n=5) and hospital pharmacists (n=3). Results: The following issues were discussed, and several recommendations were agreed upon on the following topics: a) patient profile and clinical evaluation, establishing selection criteria that should include clinical as well as social criteria; b) role of health care professionals, suggested roles for specialists in pulmonology, nurses, and hospital pharmacists; c) training by the nurse, including recommendations before initiating the training and the content of the training sessions; and d) logistic issues and follow-up, adherence, and patient support. Conclusion: We expect this proposal to increase awareness of this therapeutic alternative and facilitate the implementation of self-administration programs, thus contributing to optimizing the patient experience with AAT therapy. Further research on the outcomes of these programs, especially from the patient perspective, will also help to improve their design and implementation. This project was funded by CSL Behring España. 2023-08-30T11:04:27Z 2023-08-30T11:04:27Z 2023-08-04 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Torres-Durán M, López-Campos JL, Calle Rubio M, Montero-Martínez C, Priegue Carrera A, Amaro Rodríguez R, et al. Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin. Int J Chron Obstruct Pulmon Dis. 2023 Aug 4;18:1691–700. 1178-2005 https://hdl.handle.net/11351/10183 10.2147/COPD.S410611 37559832 001046690200001 http://hdl.handle.net/11351/10183 eng International Journal of Chronic Obstructive Pulmonary Disease;18 http://dx.doi.org/10.2147/COPD.S410611 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess application/pdf Dove Medical Press Scientia